Cell Therapy

Immunotherapies using checkpoint inhibitors such as of PD-1/PDL-1 inhibitors have already been proven successful in clinical trials. They block a mechanism that tumor cells use to hide from immune system. CAR-T cells therapy goes one step further by engineering the T cells themselves to enhance the response from the immune system against tumor cells.

Currently two CAR-T therapies have recently been approved — the first from Novartis and the second from Gilead and Kite Pharma. A lot of CAR-T therapies are running actively in clinical trials.